Retatrutide Dosing Guide for Beginners

Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials. This guide provides evidence-based dosing protocols for personal research use, based on published clinical trial data.

Research Use Only: This information is for educational purposes. Retatrutide is an investigational compound not approved for clinical use. Consult a qualified physician before beginning any peptide research protocol.

What is Retatrutide?

Retatrutide represents the next generation of incretin-based peptides. Unlike semaglutide (GLP-1 agonist) or tirzepatide (dual GLP-1/GIP agonist), retatrutide activates three metabolic pathways simultaneously:

GLP-1 receptor: Reduces appetite, slows gastric emptying
GIP receptor: Improves insulin sensitivity, reduces inflammation
Glucagon receptor: Increases energy expenditure, promotes fat oxidation

In the SURMOUNT-1 trial (Jastreboff et al., 2023), participants achieved an average of 24.2% body weight reduction at the 12mg dose over 48 weeks—significantly higher than tirzepatide (20.9%) or semaglutide (17.4%).

Clinical Trial Dosing Protocols

The SURMOUNT trials used a gradual dose escalation protocol to minimize gastrointestinal side effects:

Weeks	Dose (mg/week)	Purpose
1-4	0.5 mg	Adaptation phase
5-8	1 mg	Low therapeutic dose
9-12	2 mg	Moderate dose
13-16	4 mg	Standard dose
17-20	8 mg	High dose
21+	12 mg	Maximum dose

Beginner Protocol: Start Low, Titrate Slow

For individuals new to GLP-1 agonists, a conservative approach minimizes side effects while allowing metabolic adaptation:

12-Week Beginner Protocol

Week	Dose	What to Expect
1-2	0.25 mg	Mild appetite suppression, possible nausea (10-15% of users)
3-4	0.5 mg	Noticeable appetite reduction, 1-2% weight loss
5-6	1 mg	Stronger satiety signals, 2-4% weight loss
7-8	2 mg	Significant appetite suppression, 4-6% weight loss
9-10	4 mg	Peak appetite control, 6-10% weight loss
11-12	6-8 mg	Maintenance or continued progression

Injection schedule: Once weekly, subcutaneous (abdomen, thigh, or upper arm). Same day each week (e.g., Monday evenings).

What to Expect: Timeline & Side Effects

Weeks 1-4: Adaptation Phase

Reduced hunger, especially in evenings
Possible nausea (15-20% of users, typically mild)
Slight fatigue (metabolic adjustment)
1-3% body weight reduction

Weeks 5-12: Active Phase

Strong appetite suppression
Difficulty finishing meals
6-12% body weight reduction
Improved insulin sensitivity markers (if tracking HbA1c, fasting glucose)

Common Side Effects

Side Effect	Frequency	Management
Nausea	30-40%	Eat smaller meals, avoid high-fat foods, ginger tea
Diarrhea	15-20%	Increase fiber gradually, stay hydrated
Constipation	10-15%	Magnesium citrate (200-400mg), psyllium husk
Injection site reactions	5-10%	Rotate injection sites, allow peptide to reach room temp before injecting
Fatigue	10-15%	Ensure adequate protein intake (1.6-2.2g/kg), electrolytes

When to Adjust Dose

Plateau (weight loss stalls for 3+ weeks)

Increase dose by one step (e.g., 2mg → 4mg). Wait 4 weeks before increasing again.

Intolerable side effects

Reduce dose by one step or stay at current dose for an additional 2-4 weeks before progressing.

Rapid weight loss (>1.5% per week)

Maintain current dose. Rapid loss can lead to muscle catabolism and gallstones.

Storage & Handling in Tropical Climates

Retatrutide is temperature-sensitive. In Bali's tropical climate:

Lyophilized (powder): Store at 2-8°C (refrigerator). Stable for 12 months.
Reconstituted (mixed with bacteriostatic water): Store at 2-8°C. Use within 28 days.
Avoid: Freezing, direct sunlight, temperatures above 30°C for extended periods.
Power cuts: Use a backup cooler bag with ice packs. Peptides can tolerate room temperature for 2-4 hours without significant degradation.

For detailed storage protocols in humid climates, see our Tropical Climate Storage Guide.

Reconstitution

BioRelix supplies retatrutide as lyophilized powder (10mg vials). To prepare for injection:

Add 2ml bacteriostatic water to 10mg vial = 5mg/ml concentration
For 0.5mg dose: draw 0.1ml (10 units on insulin syringe)
For 1mg dose: draw 0.2ml (20 units)
For 2mg dose: draw 0.4ml (40 units)

Full reconstitution tutorial: How to Reconstitute Peptides.

Why BioRelix for Retatrutide in Bali

BioRelix supplies pharmaceutical-grade retatrutide in Bali with:

Third-party HPLC testing: ≥98% purity (Certificates of Analysis available)
Cold-chain delivery: Insulated containers with ice packs, same-day delivery across Bali
Complete kit: Bacteriostatic water, syringes, alcohol swabs, reconstitution guide included
Crypto + COD: USDT or cash on delivery, no personal data required

Order Retatrutide 10mg (Rp 2,800,000) | Contact: Telegram @biorelix

References

Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205-216.
Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." Lancet. 2023;402(10401):529-544.
SURMOUNT-1 Trial Data (Phase 3, Eli Lilly, 2023)

← Back to BioRelix